• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Executive summary 2020 will go down in history as the year when the global community was
awakened to the fragility of human health and the interdependence of the ecosystem …

The widespread treatment of hypertension and resultant improvement in blood pressure
have been major contributors to the dramatic age-specific decline in heart disease and …

Background In randomised controlled trials, fixed-dose combination treatments (or polypills)
have been shown to reduce a composite of cardiovascular disease outcomes in primary …

Stroke is a leading cause of permanent disability. Therefore, primary prevention of first
stroke and secondary prevention of recurrent stroke are a high priority. Primary prevention of …

Background A polypill comprising statins, multiple blood-pressure–lowering drugs, and
aspirin has been proposed to reduce the risk of cardiovascular disease. Methods Using a 2 …

Hypertension is the leading cause of death in human being, which shows high prevalence
and associated complications that increase the mortality and morbidity. Controlling blood …

Background Hypertension is the leading cause of cardiovascular disease globally. Despite
proven benefits, hypertension control is poor. We hypothesised that a comprehensive …

A key factor to successful secondary prevention of cardiovascular disease (CVD) is optimal
patient adherence to treatment. However, unsatisfactory rates of adherence to treatment for …

Cardiovascular disease is the leading cause of death globally. While pharmacological
advancements have improved the morbidity and mortality associated with cardiovascular …